HTA in the EU

A recent article compares the different HTA practices among selected EU countries (Differences in Health Technology Assessment Recommendations AmongEuropean Jurisdictions: The Role of Practice) by Vreman Rick A. et al. Published in “Value in Health”: The percentage of negative recommendations was mainly impacted by non-submission, resubmissions, price negotiations, cost-effectiveness evaluations and reassessments.

Many other components of the HTA practice can also impact this difference; willingness to pay and the importance of the assessed indications in each jurisdiction, the type of assessed health technology and comparators, the importance of the therapeutic areas, the type of effectiveness evidence, the value of measured outcomes used in the CEA for each jurisdiction, etc.